Adma Biologics Inc [NASDAQ: ADMA] loss -2.06% on the last trading session, reaching $6.19 price per share at the time. The company report on March 11, 2024 at 7:00 AM that ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®.
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM.
If compared to the average trading volume of 2.68M shares, ADMA reached a trading volume of 2673075 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adma Biologics Inc [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Adma Biologics Inc shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on July 19, 2023. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on October 13, 2022, representing the official price target for Adma Biologics Inc stock. Previously, the target price had yet another raise to $5, while Raymond James analysts kept a Strong Buy rating on ADMA stock.
The Average True Range (ATR) for Adma Biologics Inc is set at 0.23, with the Price to Sales ratio for ADMA stock in the period of the last 12 months amounting to 5.47. The Price to Book ratio for the last quarter was 10.35, with the Price to Cash per share for the same quarter was set at 0.23. Price to Free Cash Flow for ADMA in the course of the last twelve months was 350.54 with Quick ratio for the last quarter at 1.69.
Trading performance analysis for ADMA stock
Adma Biologics Inc [ADMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.82. With this latest performance, ADMA shares gained by 19.50% in over the last four-week period, additionally plugging by 74.37% over the last 6 months – not to mention a rise of 99.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 62.12, with the RSI for the last a single of trading hit 60.58, and the three-weeks RSI is set at 62.72 for Adma Biologics Inc [ADMA]. The present Moving Average for the last 50 days of trading for this stock 5.46, while it was recorded at 6.13 for the last single week of trading, and 4.23 for the last 200 days.
Adma Biologics Inc [ADMA]: A deeper dive into fundamental analysis
Adma Biologics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.69 and a Current Ratio set at 5.16.
Adma Biologics Inc [ADMA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adma Biologics Inc posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.04/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMA.
An analysis of Institutional ownership at Adma Biologics Inc [ADMA]
The top three institutional holders of ADMA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ADMA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ADMA stock with ownership which is approximately 5.8325%.
